Novo Nordisk
News/ News/ Sales and Marketing
Insulin producers face fresh lawsuit in US over pricing
Phil Taylor
Drug pricing, Eli Lilly, insulin, litigation, Novo Nordisk, Sanofi
0 Comment
Novo Nordisk forges close ties with biotech VC Flagship
Phil Taylor
drug discovery, Flagship Pioneering, Novo Nordisk, partnering, R&D
0 Comment
Novo Nordisk once-weekly insulin clears first phase 3 test
Phil Taylor
Diabetes, drug delivery, insulin, insulin icodec, metabolic disease, Novo Nordisk
0 Comment
R&D/ Views & Analysis/ Views and analysis
Big pharma vs small diseases: Tackling rare diseases
Jonah Comstock
Alexion, Novo Nordisk, pharma, rare disease
0 Comment
Lilly fires a broadside at Novo Nordisk’s obesity ambitions
Phil Taylor
Eli Lilly, Novo Nordisk, obesity, tirzepatide, Wegovy
0 Comment
R&D/ Views & Analysis/ Views and analysis
No room for commercial competition in sustainable pharma
Amanda Barrell
AstraZeneca, GlaxoSmithKline, Novo Nordisk, pharma, Sustainability
0 Comment
Digital/ Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
IWD: Spotlight on women in life sciences
Eloise McLennan
Envair Technology, International Women's Day, Life Sciences, Merck, Novo Nordisk, STEM
0 Comment
News/ News/ Sales and Marketing
Novo Nordisk eyes obesity sales of $3.7bn in 2025 thanks to Wegovy
Phil Taylor
Novo Nordisk, obesity, Saxenda, Wegovy
0 Comment